|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Prepaid expenses - research and development | ||||||||||||||||||||
| Subscription receivable | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Deficiency | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accrued expenses | ||||||||||||||||||||
| Accrued expenses - related parties | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accrued interest | ||||||||||||||||||||
| Accrued interest - related parties | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total notes payable | ||||||||||||||||||||
| Notes payable - related parties | ||||||||||||||||||||
| Convertible notes payable, net of debt discount of $12,756 and $71,124 as of March 31, 2022 and December 31, 2021, respectively | ||||||||||||||||||||
| Convertible notes payable | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total convertible notes payable | ||||||||||||||||||||
| Convertible notes payable - related parties, net of debt discount of $147,230 and $0 as of December 31, 2022 and 2021, respectively | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Derivative liabilities | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total derivative liabilities | ||||||||||||||||||||
| Financing liability | ||||||||||||||||||||
| Advances payable | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total advances payable | ||||||||||||||||||||
| Advances payable - related party | ||||||||||||||||||||
| Advances payable - related party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Accrued dividend payable | ||||||||||||||||||||
| Total accrued dividend payable | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders’ Deficiency: | ||||||||||||||||||||
| Preferred stock, value | ||||||||||||||||||||
| Series A Convertible Preferred Stock | ||||||||||||||||||||
| Series B Convertible Preferred Stock | ||||||||||||||||||||
| Series C Convertible Preferred Stock | ||||||||||||||||||||
| Common Stock, $0.001 par value, 200,000,000 shares authorized; 45,038,244 shares issued and outstanding as of March 31, 2025 and December 31, 2024 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders’ Deficiency | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Deficiency | ||||||||||||||||||||
Loading...